© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thyroid Cancers
Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer
September 19, 2020
Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
FDA Grants Orphan Drug to Bispecific Antibody as Treatment of Thymic Epithelial Tumors
September 08, 2020
The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.
FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers
September 05, 2020
The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.
Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric Patients
September 03, 2020
The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.
Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness Month
September 02, 2020
In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the evolution she has observed in thyroid cancer in terms of the use of targeted therapies and other important milestones for this patient population.
Is ATA Risk Stratification Still a Reliable Predictor of Response in DTC?
September 02, 2020
A real-world study assessed the performance of this system in patients with differentiated thyroid cancer and discovered that the system is reliable for predicting short-term outcomes.
Selpercatinib May Be New Standard of Care for RET-Altered Thyroid Cancers, Study Shows
August 26, 2020
Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they received prior vandetanib or cabozantinib in the phase 1/2 LIBRETTO-001 study.
A 64-Year-Old Man With Differentiated Thyroid Cancer
August 26, 2020
A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.
Overdiagnosis Raises Concerns as the Incidence of Thyroid Cancer Cases Rises Globally
August 18, 2020
Experts suspect the rising incidence of thyroid cancer may be related to the growing scrutiny of the thyroid gland with ultrasonography or other diagnostic techniques, but overdiagnosis may be a growing factor in the field.
Larotrectinib Efficacy Highlights Importance of Genomic Testing in Thyroid Cancer
August 18, 2020
Marcia Brose, MD, PhD, discusses how the thyroid cancer treatment landscape will be impacted by the positive findings regarding larotrectinib in the presence of a TRK fusion.